New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
08:00 EDTRDY, MNK, ACT, PRGO, IPXL, TEVA, MNTA, HITKBMO Capital to hold a summit
BMO Generic Drug Summit is being held in Orlando on February 19.
News For ACT;HITK;IPXL;MNK;MNTA;PRGO;RDY;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 12, 2015
07:53 EDTRDYDr. Reddy's Labs reports Q4 EPS 49c vs. 45c last year
Subscribe for More Information
07:52 EDTMNTALeerink to hold a tour
Subscribe for More Information
May 11, 2015
19:15 EDTIPXLOn The Fly: After Hours Movers
Subscribe for More Information
16:43 EDTIPXLImpax performs GMP, pre-approval inspections of Impax Hayward facility
Subscribe for More Information
16:15 EDTIPXLImpax says FDA issued Form 483 after facility inspection
Subscribe for More Information
16:14 EDTIPXLImpax reaffirms outlook for 2015
Impax still sees 2015 adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, adjusted total research and development expenses across the generic and brand divisions of $80M-$85M and capital expenditures of $45M-$50M.
16:13 EDTIPXLImpax reports Q1 adjusted EPS 9c, consensus 18c
Reports Q1 revenue $143.1M, consensus $146.13M. The company said, "This quarter's revenues were negatively impacted by the later than anticipated close of the Tower acquisition, the delayed launch of lamotrigine ODT, which was launched in April due to delayed receipt of inventory from our supplier, and the deferred recognition of product sales from the launch of RYTARY. In addition, product sales mix in the combined portfolio as well as costs related to successfully launching RYTARY and the financing of the Tower acquisition led to a reduction in our first quarter earnings."
15:00 EDTIPXLNotable companies reporting after market close
Subscribe for More Information
14:27 EDTTEVACowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
12:51 EDTACTOn The Fly: Top stock stories at midday
Subscribe for More Information
11:53 EDTTEVA, PRGOTeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
May 10, 2015
19:25 EDTACT, TEVACourt rejects claim that drugmakers misled opiate patients, Bloomberg says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use